Dolphin K is generally used for managing symptoms related to physical discomfort and inflammatory or irritative states. It is applied in scenarios where additional management of discomfort is required to support patient well-being, focusing on short-term symptomatic assistance. Its therapeutic use is relevant in clinical settings that involve acute or unstable symptom patterns.

The medication is commonly used to help manage symptoms associated with conditions such as osteoarthritis, rheumatoid arthritis, primary dysmenorrhea, and post-operative or post-traumatic pain. This focus may help support the patient during phases when symptoms become more noticeable.

Supportive Care for Ongoing Joint Discomfort

This is commonly used across conditions presenting with recurrent or episodic manifestations, such as various types of arthritis. It may assist with managing stiffness and other symptoms related to inflammatory or irritative states. This contributes to improved comfort and supports the patient during difficult episodes by easing distress during symptomatic periods.

Quick Fact: Support for Inflammatory Symptoms Dolphin K is relevant for easing symptoms that interfere with daily comfort, such as localized swelling and tenderness associated with joint or soft tissue inflammation.

Regulatory References

1. NIH DailyMed official prescribing information

Dolphin K (diclofenac potassium) is subject to strict eligibility rules defined by government regulatory authorities, primarily focusing on patient age, pre-existing conditions, and physiological status.

Contraindicated Populations (Must Not Use)

Regulatory labeling prohibits the use of Dolphin K in patients with the following conditions:

• Known hypersensitivity to diclofenac, aspirin, or any other Nonsteroidal Anti-Inflammatory Drug (NSAID) (e.g., history of asthma or allergic-type reactions).
• Active gastric or intestinal ulceration, bleeding, or perforation.
• Severe cardiac failure (NYHA Class II-IV), severe hepatic failure, or severe renal failure.
• The last trimester of pregnancy (starting at about 30 weeks gestation).
• Treatment of peri-operative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery.

Age and Condition-Based Restrictions

• Pediatric Use: The use of oral tablets is generally not recommended for children and adolescents below 14 years of age. Eligibility for other formulations may begin at 12 years of age for specific indications.
• Older Adults: Elderly patients (65 years and above) require treatment with the lowest effective dose for the shortest duration due to an increased risk of serious adverse reactions, especially gastrointestinal bleeding.
• Cardiovascular and Organ Impairment: Caution and close medical supervision are required for patients with established cardiovascular disease (e.g., ischemic heart disease, uncontrolled hypertension) or mild to moderate renal or hepatic impairment. Use may be restricted to doses leq 100 mg/day in certain cardiovascular risk groups.
• Pregnancy and Lactation: Use is restricted between 20 and 30 weeks gestation. Diclofenac is excreted into breast milk in small amounts, and use during lactation requires caution.

Official Regulatory Interaction Profile

The interaction profile of Diclofenac potassium is defined by its potential to affect drug metabolism and increase the risk of adverse outcomes when combined with certain medicines or substances, according to government regulatory documentation.

Interaction Classification	Interacting Agents / Classes	Regulatory Constraint / Outcome
Contraindicated Combinations	Perioperative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery; Other systemic NSAIDs	Formal prohibition of co-administration or procedural use.
Pharmacodynamic Risk	Warfarin (Anticoagulants), Aspirin (Analgesic doses), SSRIs, Corticosteroids, Alcohol	Synergistic increase in the risk of serious gastrointestinal (GI) bleeding or ulceration.
Pharmacokinetic Alteration	Lithium, Methotrexate, Digoxin	Reduced renal clearance of these co-administered drugs, leading to elevated plasma levels and potential toxicity.
Metabolic Pathway Interference	CYP2C9 Inhibitors (e.g., Voriconazole); CYP2C9 Inducers (e.g., Rifampin)	Inhibitors enhance Diclofenac exposure; Inducers compromise its efficacy via effects on the CYP2C9 enzyme.

Combinations with ACE Inhibitors or ARBs may diminish their antihypertensive effect and require caution, particularly in elderly or renal impairment populations, due to risk of worsening kidney function. A mandatory timing restriction requires avoiding Diclofenac for two days before, the day of, and two days following administration of Pemetrexed. The overall structure reflects the established NSAID interaction profile concerning GI, renal, and drug metabolism pathways.

The mechanism of action for Dolphin k is primarily centered on the modulation of excitatory neurotransmission within the central nervous system. The drug functions as a non-competitive antagonist of the N-methyl-D-aspartate receptor (NMDAR), an ionotropic receptor for the excitatory neurotransmitter glutamate. Dolphin k acts as an open-channel blocker, physically binding within the ion channel pore to impede the influx of Ca^2+ and Na^+ ions.

This primary action triggers a subsequent mechanistic cascade involving the transient activation of the mTOR signaling pathway. This intracellular cascade stimulates the rapid synthesis of synaptic proteins, which promotes synaptic plasticity and the formation of new neural connections in key brain regions. This modulation of cellular function underlies the prolonged downstream consequences of the drug.

Simultaneously, Dolphin k engages in secondary modulation of other critical neurochemical systems, including dopaminergic, serotonergic, and opioid pathways. These broad interactions influence downstream biological consequences, resulting in alterations in pain processing, changes in conscious state, and modulation of central arousal and sympathetic nervous system activity.

How to Use Dolphin k: Administration Guidelines

Dolphin k (Diclofenac potassium) is used orally across various formulations, including film-coated tablets (50 mg), capsules (25 mg), and powder for oral solution (50 mg packets). Administration is consistently based on using the lowest effective dose for the shortest duration possible.

---

Standard Dosing and Frequency

Application	Typical Dose & Frequency	Maximum Daily Dose
Acute Pain	50 mg up to three times daily, or as-needed.	150 mg (tablets)
Acute Migraine	Single 50 mg dose.	Up to 200 mg (specific rapid-acting forms)

For chronic conditions, the usual maintenance dose of the tablet is taken two to four times daily. Treatment is typically intended for short-term use to manage acute episodes of pain or inflammation.

---

Administration Conditions and Adjustments

• Oral Solution Preparation: The single-dose powder packet must be mixed immediately with 30 to 60 mL of water only and consumed right away. This specific formulation should be taken on an empty stomach for acute treatment to enhance speed of onset.
• Tablet/Capsule Intake: While tablets may be taken with or after food, some rapid-acting forms are recommended for use before meals.
• Dose Adjustment: Standard practice involves initiating treatment for older adults and patients with mild to moderate hepatic impairment at the lowest effective dose.

Research Evidence / Overview of Studies for Dolphin K

---

Evidence for Use in Acute Pain and Migraine Attacks

Diclofenac potassium was studied for conditions characterized by episodic manifestations, such as short-term post-operative pain and single migraine attacks. Studies conducted during periods of increased symptom activity primarily used Randomized Controlled Trials (RCTs), where the medicine was compared against an inactive substance (placebo). These studies monitored patient-reported outcomes describing perceived discomfort over defined time intervals.

Studies monitored responses over defined time intervals, often as a single observation period lasting only a few hours. Research examined outcomes related to physical discomfort and how quickly these were monitored. Findings describe patterns observed in the studies related to the use of rescue medication in the hours following administration.

When studied for migraine attacks, research explored outcomes related to physical discomfort, specifically monitoring patterns related to participants reporting a change to low pain intensity within two hours of treatment. Studies reported how symptoms evolved in the observed populations, including outcomes monitored for conditions that may include light or sound sensitivity. However, research has primarily explored single-dose or very short-term (up to 72-hour) outcomes, and long-term effects are not fully established for managing recurring acute pain episodes.

Research Outcomes for Pain Relief Intensity

The primary measures used in clinical trials were often centered on patient-reported outcomes describing perceived discomfort. These included specialized scales to monitor pain intensity and functional status. For migraines, studies monitored outcomes related to physical discomfort as measured by reported intensity. Research provides context but not individual predictions, as study results reflect the specific conditions under which they were conducted.

---

Evidence for Use in Primary Dysmenorrhea

The research base for primary dysmenorrhea (menstrual pain) is primarily built upon smaller, randomized, placebo-controlled crossover studies. These studies involved young women experiencing pain in conditions characterized by fluctuating or episodic manifestations. The research focused on studies conducted during periods of increased symptom activity, monitoring menstrual pain intensity and patterns related to rescue medication over the course of a single cycle.

Trial findings describe patterns observed in the studies related to outcomes linked to inflammatory or irritative states. However, studies reported that sample sizes were modest and follow-up durations were limited to the acute phase of one or two cycles; data for long-term management of dysmenorrhea are still emerging.

---

Evidence for Use in Chronic Inflammatory Joint Conditions

Diclofenac potassium was studied for conditions involving periods of heightened symptoms, such as Osteoarthritis (OA) and Rheumatoid Arthritis (RA). The evidence base includes numerous Randomized Controlled Trials (RCTs) designed to evaluate outcomes related to systemic or functional imbalance over intermediate time intervals.

Research examined outcomes reflecting daily functioning or activity level, using specialized tools like the WOMAC scale to measure joint pain and stiffness. Studies explored how symptoms evolved in the observed populations over defined follow-up durations, typically ranging from four weeks to three months. Findings describe patterns observed in the studies related to daily functioning or activity level.

---

What is Still Uncertain About Dolphin K Research

Evidence highlights what is known and what is still uncertain regarding this medicine. Research describes the structure of the evidence base, which shows that follow-up durations were limited in many acute studies, and sample sizes were modest in some smaller trials. The research indicates evidence is limited for long-term effects beyond the typical follow-up periods seen in the intermediate-term trials.

Findings describe group patterns, not personal outcomes, and research provides context but not individual predictions.

Key Studies & References

1. Diclofenac Potassium Tablets, USP: Full Prescribing Information (Indications and Usage)

How to Store and Dispose of Dolphin K

Official storage and disposal instructions ensure the medicine remains effective and is handled safely. Dolphin K (Diclofenac potassium) must be stored out of the sight and reach of children and pets, following the mandatory regulatory requirement to store locked up. For product stability, the medication container should be kept tightly closed to protect against moisture and must be kept from freezing.

All medicines must be used only up to the expiry date stated on the packaging. When discarding unused or expired product, do not throw away any medicines via wastewater or household waste. The active substance is classified as toxic to aquatic life, requiring disposal through a pharmacist or an approved hazardous waste collection point in accordance with local, regional, and national regulations.